[comparing two treatments in resolving a retinal/eye disorder] Per oral Eplerenone and topical nepafenac are being compared in the treatment of central serous chorioretinopathy.

Oral mineralocorticoid-receptor antagonist vs 0.3 % nepafenac for the treatment of acute central serous chorioretinopathy: a prospective, randomized comparative study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240404061413N1

Enrollment

110

Registered

2024-05-01

Start date

2024-04-15

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute central serous retinopathy in a eye retinal disorder which involves by serous retinal detachment (SRD) due to one or more leakage areas from the choroid through a defect in the retinal pigment epithelium (RPE), and a dome shaped serous pigment epithelial detachment (PEDs).. Central serous chorioretinopathy

Interventions

Intervention 1: Intervention group:1. Oral eplerenone 50 mg in two divided doses (25 mg tablet twice day)12 hours apart for 6 weeks will be given. Medicine taken after meals at the same time each day.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: acute central serous chorioretinopathy

Exclusion criteria

Exclusion criteria: chronic central serous chorioretinopathy contraindications to oral eplerenone or topical nepafenac retinal or choroidal pathologies severe ocular disease

Design outcomes

Primary

Measure	Time frame
Primary outcome measures were best corrected visual acuity comparisons between the treatment group (oral eplerenone & topical nepafenac) in the study eye at every visit. Timepoint: Before intervention and 6, 12 and 24 weeks after either intervention. Method of measurement: optometrist/technician will measure the vision with a Snellen chart as letters read with prescription glasses , if any.;Primary outcome measures were subretinal fluid height measurements between the treatment group (oral eplerenone & topical nepafenac) in the study eye at every visit. Timepoint: Before intervention and 6, 12 and 24 weeks after either intervention. Method of measurement: optical coherence tomography.;Primary outcome measures were sub-foveal choroidal thickness measurements between the treatment group (oral eplerenone & topical nepafenac) in the study eye at every visit. Timepoint: Before intervention and 6, 12 and 24 weeks after either intervention. Method of measurement: optical coherence tomography.	—

Measure

Time frame

Primary outcome measures were best corrected visual acuity comparisons between the treatment group (oral eplerenone & topical nepafenac) in the study eye at every visit. Timepoint: Before intervention and 6, 12 and 24 weeks after either intervention. Method of measurement: optometrist/technician will measure the vision with a Snellen chart as letters read with prescription glasses , if any.;Primary outcome measures were subretinal fluid height measurements between the treatment group (oral eplerenone & topical nepafenac) in the study eye at every visit. Timepoint: Before intervention and 6, 12 and 24 weeks after either intervention. Method of measurement: optical coherence tomography.;Primary outcome measures were sub-foveal choroidal thickness measurements between the treatment group (oral eplerenone & topical nepafenac) in the study eye at every visit. Timepoint: Before intervention and 6, 12 and 24 weeks after either intervention. Method of measurement: optical coherence tomography.

—

Secondary

Measure	Time frame
Secondary outcome was serum potassium level evaluation in oral eplerenone group. Timepoint: Before intervention and 6 weeks. Method of measurement: Serum potassium levels will be measured with a lab kit at six weeks to assess any derangements.;Secondary outcome were topical nepafenac drug tolerance evaluated at each visit. Timepoint: Before intervention and 6, 12 , 24 weeks after either intervention. Method of measurement: Slit lamp examination will be done to determine any possible side effects related to topical nepafenac (primarily corneal and conjunctival side effects).	—

Measure

Time frame

Secondary outcome was serum potassium level evaluation in oral eplerenone group. Timepoint: Before intervention and 6 weeks. Method of measurement: Serum potassium levels will be measured with a lab kit at six weeks to assess any derangements.;Secondary outcome were topical nepafenac drug tolerance evaluated at each visit. Timepoint: Before intervention and 6, 12 , 24 weeks after either intervention. Method of measurement: Slit lamp examination will be done to determine any possible side effects related to topical nepafenac (primarily corneal and conjunctival side effects).

—

Countries

Pakistan

Contacts

Public ContactAhmad hasan alizai

Alshifa trust eye hospital

alizai111@gmail.com+92 321 5180996

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026